Innovative Medicine — Acquisition related costs
Business Segments · Acquisition related costsAnalysis
StatementSegment
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ3 2025
Last reportedQ3 2025
Rolls up toAcquisition and integration costs
How to read this metric
An increase reflects active M&A activity, which may temporarily depress earnings but is intended to drive long-term growth.
Detailed definition
These are the costs directly attributable to the acquisition of businesses or assets within the Innovative Medicine segm...
Peer comparison
Commonly reported by large-cap pharmaceutical companies during periods of aggressive portfolio expansion.
Metric ID:
jnj_segment_innovative_medicine_acquisition_related_costsHistorical Data
1 periods
| Q3 '25 | |
|---|---|
| Value | $100.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — acquisition related costs?
- Johnson & Johnson (JNJ) reported innovative medicine — acquisition related costs of $100.00M in Q3 2025.
- What does innovative medicine — acquisition related costs mean?
- Expenses incurred specifically to complete and integrate business acquisitions within the Innovative Medicine segment.